TEMPUS AI INC CLASS A (TEM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for TEM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| TEM | Director | 62 | ["Professor of Biochemistry & Molecular Biology","directs the Innovative Genomics Institute"] | ["Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| JNJ | Independent Director | 62 | ["Principal Investigator, Doudna Lab","Founder, Innovative Genomics Institute","Professor, Biochemistry, Biophysics and Structural Biology","Founder, Laboratory for Genomics Research","Nobel Prize Recipient in Chemistry (2020)","Pioneer in the field of biochemistry, having co-discovered the simplified genome editing technique CRISPR-Cas9","Expertise in scientific research and innovation","Leader in integration of scientific research and ethics"] | ["Nominating & Corporate Governance","Science & Technology"] | 2026 |
Biography sourced from the proxy statement filing.
Jennifer A. Doudna, Ph.D. has served as a member of our board of directors since April 2021. Dr. Doudna has also served on the board of directors of Johnson & Johnson since April 2018. Since July 2002, Dr. Doudna has served as a Professor of Biochemistry & Molecular Biology at University of California, Berkeley, where she directs the Innovative Genomics Institute, a joint UC Berkeley-UC San Francisco center, holds the Li Ka Shing Chancellor s Professorship in Biomedical and Health, and is the Chair of the Chancellor s Advisory Committee on Biology. Since 2002, Dr. Doudna has served as Principal Investigator at the Doudna Lab at UC Berkeley. Dr. Doudna has founded and served on the Scientific Advisory Boards of Caribou Biosciences, Inc. and Intellia Therapeutics, Inc., since 2010, both leading CRISPR genome engineering companies, since 2010. She has also been an Investigator with the Howard Hughes Medical Institute since 1997. Dr. Doudna is the recipient of numerous scientific awards in biochemistry and genetics, including the Nobel Prize in Chemistry in 2020. Dr. Doudna holds a bachelor s degree from Pomona College and a Ph.D. from Harvard Medical School. We believe that Dr. Doudna is qualified to serve on our board of directors because of her expertise in scientific research and innovation.